Drugs.com - Clinical Trials

Signal12 Achieves FDA Alignment, Accelerating Pro-ocular™ Towards Phase 3 Clinical Trials for Ocular Graft-versus-Host Disease

BOSTON, March 18, 2025 /PRNewswire/ -- Signal12, Inc. (Signal12), a clinical-stage ophthalmic pharmaceutical company focused on first-of-a-kind patented technologies that enable existing drugs to act through unique neural pathways, today announced...

Mar 19, 2025 - 21:27
 0
Signal12 Achieves FDA Alignment, Accelerating Pro-ocular™ Towards Phase 3 Clinical Trials for Ocular Graft-versus-Host Disease
BOSTON, March 18, 2025 /PRNewswire/ -- Signal12, Inc. (Signal12), a clinical-stage ophthalmic pharmaceutical company focused on first-of-a-kind patented technologies that enable existing drugs to act through unique neural pathways, today announced...
Read More

Tags:

Previous Article

Henlius Receives Orphan-Drug Designation for HLX22 (Innovative anti-HER2 mAb) in...

Next Article

GRIN Therapeutics Receives FDA Orphan Drug Designation for Radiprodil for the Tr...

Related Posts

Innovent Receives Second Fast Track Designation from the U.S. FDA for IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Squamous Non-Small Cell Lung Cancer

Innovent Receives Second Fast Track Designation from th...

Feb 27, 2025  0

U.S. FDA Grants Orphan Drug Designation to Ariceum Therapeutics’ Proprietary Radiopharmaceutical Cancer Therapy

U.S. FDA Grants Orphan Drug Designation to Ariceum Ther...

Feb 10, 2025  0

Kura Oncology and Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial and Positive FDA Feedback for Upcoming Frontline Combination Trial Designs

Kura Oncology and Kyowa Kirin Announce Positive Ziftome...

Feb 9, 2025  0